Edwards Lifesciences Corporation Investors: Company Investigated by the Portnoy Law Firm

Core Insights - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Edwards Lifesciences Corporation and may file a class action on behalf of affected investors [1][2] Financial Performance - On July 24, 2024, Edwards reported second-quarter financial results for fiscal 2024 that were below expectations and reduced its full-year 2024 revenue guidance for its Transcatheter Aortic Valve Replacement (TAVR) platform [3] - The slowdown in TAVR was attributed to the growth of structural heart therapies, which impacted hospital workflows and led to underutilization of TAVR despite claims of a significantly undertreated patient population [3] - Edwards announced three acquisitions during the quarter aimed at enhancing treatments alternative to TAVR, indicating awareness of the decelerating growth of the TAVR platform [3] Stock Market Reaction - Following the disappointing disclosures, Edwards' stock price plummeted from $86.95 per share on July 24, 2024, to $59.70 per share on July 25, 2024, marking a decline of approximately 31.34% in a single trading day [4]